HomepageJAZZ • NASDAQ
add
Jazz Pharmaceuticals PLC
$ 101,55
Na sluitingstijd:(0,00%)0,00
$ 101,55
Gesloten: 16 apr, 16:20:00 GMT-4 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$ 102,91
Dag-range
$ 100,42 - $ 103,96
Jaar-range
$ 95,49 - $ 148,06
Beurswaarde
6,17 mld. USD
Gem. volume
1,43 mln.
Koers/winst
11,74
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 1,09 mld. | 7,53% |
Bedrijfskosten | 768,69 mln. | 9,42% |
Netto inkomsten | 191,12 mln. | 102,98% |
Netto winstmarge | 17,56 | 88,82% |
Winst per aandeel | 6,60 | 31,47% |
EBITDA | 396,98 mln. | 0,82% |
Effectief belastingtarief | -43,48% | — |
Balans
Totale activa
Totale passiva
| (USD) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 2,99 mld. | 83,66% |
Totale activa | 12,01 mld. | 5,43% |
Totale passiva | 7,92 mld. | 3,42% |
Totaal aandelenvermogen | 4,09 mld. | — |
Uitstaande aandelen | 60,73 mln. | — |
Koers-boekwaardeverhouding | 1,52 | — |
Rendement op activa | 4,71% | — |
Rendement op kapitaal | 5,54% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 191,12 mln. | 102,98% |
Operationele kasstroom | 398,58 mln. | 138,19% |
Kasstroom uit beleggingen | -193,29 mln. | -289,87% |
Kasstroom uit financiering | -8,28 mln. | 91,75% |
Nettomutatie in liquide middelen | 194,73 mln. | 14,13% |
Vrije kasstroom | 466,32 mln. | 470,30% |
Over
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Opgericht
2003
Website
Werknemers
2.800
